Goldman Sachs’s Cullinan Oncology CGEM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.29M | Buy |
702,138
+53,181
| +8% | +$400K | ﹤0.01% | 2748 |
|
|
2025
Q1 | $4.91M | Sell |
648,957
-36,417
| -5% | -$276K | ﹤0.01% | 2756 |
|
|
2024
Q4 | $8.35M | Sell |
685,374
-15,178
| -2% | -$185K | ﹤0.01% | 2473 |
|
|
2024
Q3 | $11.7M | Buy |
700,552
+247,765
| +55% | +$4.15M | ﹤0.01% | 2128 |
|
|
2024
Q2 | $7.9M | Buy |
452,787
+283,420
| +167% | +$4.94M | ﹤0.01% | 2277 |
|
|
2024
Q1 | $2.89M | Buy |
169,367
+41,052
| +32% | +$700K | ﹤0.01% | 2960 |
|
|
2023
Q4 | $1.31M | Buy |
128,315
+42,204
| +49% | +$430K | ﹤0.01% | 3475 |
|
|
2023
Q3 | $779K | Sell |
86,111
-15,316
| -15% | -$139K | ﹤0.01% | 3667 |
|
|
2023
Q2 | $1.09M | Sell |
101,427
-78,393
| -44% | -$844K | ﹤0.01% | 3566 |
|
|
2023
Q1 | $1.84M | Buy |
179,820
+11,930
| +7% | +$122K | ﹤0.01% | 3276 |
|
|
2022
Q4 | $1.77M | Sell |
167,890
-158,860
| -49% | -$1.68M | ﹤0.01% | 3355 |
|
|
2022
Q3 | $4.19M | Buy |
326,750
+161,441
| +98% | +$2.07M | ﹤0.01% | 2777 |
|
|
2022
Q2 | $2.12M | Buy |
165,309
+81,658
| +98% | +$1.05M | ﹤0.01% | 3400 |
|
|
2022
Q1 | $876K | Buy |
83,651
+3,250
| +4% | +$34K | ﹤0.01% | 4204 |
|
|
2021
Q4 | $1.24M | Sell |
80,401
-77,100
| -49% | -$1.19M | ﹤0.01% | 3858 |
|
|
2021
Q3 | $3.56M | Buy |
157,501
+145,148
| +1,175% | +$3.28M | ﹤0.01% | 3038 |
|
|
2021
Q2 | $318K | Sell |
12,353
-43,707
| -78% | -$1.13M | ﹤0.01% | 4671 |
|
|
2021
Q1 | $2.34M | Buy |
+56,060
| New | +$2.34M | ﹤0.01% | 3246 |
|